Paul Diaz - DaVita HealthCare Independent Director
| DVA Stock | USD 166.99 1.48 0.89% |
Director
Mr. Paul J. Diaz serves as Independent Director of DaVita HealthCare Partners Inc. Mr. Diaz was one of our directors since July 2007. Mr. Diaz currently serves as a general partner of Cressey Company, a private equity firm focused exclusively on investing in and building healthcare businesses, a position he has held since September 2017. Mr. Diaz was an operating partner at Cressey Company from March 2016 to September 2017. Since August 2014, Mr. Diaz has served as a partner at Guidon Partners LP, a private investment partnership. He served as executive vice chairman of Kindred Healthcare, Inc., a provider of longterm healthcare services in the United States, from March 2015 to March 2016, chief executive officer from January 2004 to March 2015, as well as president from January 2002 to May 2012 and as chief operating officer from January 2002 to December 2003. Prior to joining Kindred, Mr. Diaz was the managing member of Falcon Capital Partners, LLC, a private investment and consulting firm, and from 1996 to July 1998, Mr. Diaz served in various executive capacities with Mariner Health Group, Inc., a healthcare facility operator, including as executive vice president and chief operating officer. Mr. Diaz serves on the board of Performance Health, a private medical supply distribution company, the board of trustees of Johns Hopkins Medicine and the board of visitors of the Georgetown University Law Center. Mr. Diaz also previously served on the board of PharMerica Corporationrationration, and from May 2002 until July 2018, served on the board of Kindred. Mr. Diaz is an experienced business leader with significant experience in the healthcare industry and brings an understanding of the operational, financial and regulatory aspects of our industry and business. since 2007.
| Age | 58 |
| Tenure | 17 years |
| Address | 2000 16th Street, Denver, CO, United States, 80202 |
| Phone | 720 631 2100 |
| Web | https://www.davita.com |
Paul Diaz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Diaz against DaVita HealthCare stock is an integral part of due diligence when investing in DaVita HealthCare. Paul Diaz insider activity provides valuable insight into whether DaVita HealthCare is net buyers or sellers over its current business cycle. Note, DaVita HealthCare insiders must abide by specific rules, including filing SEC forms every time they buy or sell DaVita HealthCare'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Diaz over six months ago Disposition of 95000 shares by Paul Diaz of Myriad Genetics at 25.2084 subject to Rule 16b-3 | ||
Paul Diaz over six months ago Disposition of 27233 shares by Paul Diaz of Myriad Genetics at 22.24 subject to Rule 16b-3 | ||
Paul Diaz over six months ago Disposition of 30610 shares by Paul Diaz of Myriad Genetics at 21.16 subject to Rule 16b-3 | ||
Paul Diaz over six months ago Acquisition by Paul Diaz of 246248 shares of Myriad Genetics subject to Rule 16b-3 |
DaVita HealthCare Management Efficiency
The company has Return on Asset of 0.0694 % which means that on every $100 spent on assets, it made $0.0694 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4488 %, implying that it generated $0.4488 on every 100 dollars invested. DaVita HealthCare's management efficiency ratios could be used to measure how well DaVita HealthCare manages its routine affairs as well as how well it operates its assets and liabilities. At present, DaVita HealthCare's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.15, whereas Return On Assets are forecasted to decline to 0.04. At present, DaVita HealthCare's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Return On Tangible Assets is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 10.2 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Meg Crofton | HCA Holdings | 67 | |
| John Clerico | Community Health Systems | 79 | |
| Kathleen Gilmartin | US Physicalrapy | 69 | |
| Charles Elson | Encompass Health Corp | 60 | |
| Reginald Swanson | US Physicalrapy | 67 | |
| Michael Dinkins | Community Health Systems | 67 | |
| Julia North | Community Health Systems | 72 | |
| Harry Chapman | US Physicalrapy | 76 | |
| Mark Foletta | AMN Healthcare Services | 60 | |
| Donald Correll | Encompass Health Corp | 70 | |
| Charles Holliday | HCA Holdings | 73 | |
| Robert Dennis | HCA Holdings | 67 | |
| Martha Marsh | AMN Healthcare Services | 72 | |
| Wayne Riley | HCA Holdings | 61 | |
| Richard Fisher | Tenet Healthcare | 72 | |
| Meghan FitzGerald | Tenet Healthcare | 50 | |
| Michael Johns | AMN Healthcare Services | 78 | |
| Ross Comeaux | Community Health Systems | N/A | |
| John Maupin | Encompass Health Corp | 73 | |
| Tammy Romo | Tenet Healthcare | 58 | |
| Richard Mark | Tenet Healthcare | 65 | |
Management Performance
| Return On Equity | 0.45 | ||||
| Return On Asset | 0.0694 |
DaVita HealthCare Leadership Team
Elected by the shareholders, the DaVita HealthCare's board of directors comprises two types of representatives: DaVita HealthCare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DaVita. The board's role is to monitor DaVita HealthCare's management team and ensure that shareholders' interests are well served. DaVita HealthCare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DaVita HealthCare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Hearty, Chief Compliance Officer | ||
| Shawn Guertin, Director | ||
| Javier Rodriguez, Chief Executive Officer, Director | ||
| Paula Price, Independent Director | ||
| Paul Diaz, Independent Director | ||
| Misha Palecek, Chief Business | ||
| Christopher Berry, Group Officer | ||
| Christopher CPA, Group Officer | ||
| Jeffrey Giullian, Chief Care | ||
| John Nehra, Independent Director | ||
| Phyllis Yale, Independent Director | ||
| BSN MBA, Chief Officer | ||
| Madhu Narasimhan, Chief Officer | ||
| Mandy Hale, Chief Officer | ||
| Jim Gustafson, Vice President - Investor Relations | ||
| John Winstel, Chief Accounting Officer, Group Vice President | ||
| Kenneth Smith, Chief Officer | ||
| Jessica Hergenreter, Chief Officer | ||
| Gregory Moore, Independent Director | ||
| David Roer, Chief Medical Officer - DaVita Integrated Kidney Care | ||
| FRCPC MD, Chief Operations | ||
| Nic Eliason, Group Relations | ||
| Atul Mathur, Executive Vice President of Global Operations | ||
| Joel Ackerman, Chief Financial Officer, Treasurer | ||
| Kathleen Waters, Chief Legal and Public Affairs Officer | ||
| Pamela Arway, Independent Chairman of the Board | ||
| Michael Staffieri, Chief Operating Officer- DaVita Kidney Care | ||
| Pascal Desroches, Independent Director | ||
| David Maughan, Chief Officer | ||
| LeAnne Zumwalt, Group Vice President - purchasing and government affairs | ||
| Kenny Gardner, Chief People Officer - DaVita Kidney Care | ||
| Barbara Desoer, Independent Director | ||
| Mihran Naljayan, Chief Medical Officer - Home Modalities | ||
| Charles Berg, Independent Director | ||
| MSc MD, Chief International |
DaVita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DaVita HealthCare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | ||||
| Return On Asset | 0.0694 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 24.68 B | ||||
| Shares Outstanding | 82.02 M | ||||
| Shares Owned By Insiders | 48.53 % | ||||
| Shares Owned By Institutions | 50.24 % | ||||
| Number Of Shares Shorted | 4.28 M | ||||
| Price To Earning | 11.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DaVita HealthCare offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DaVita HealthCare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Davita Healthcare Partners Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Davita Healthcare Partners Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DaVita HealthCare Partners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DaVita HealthCare. If investors know DaVita will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DaVita HealthCare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 9.29 | Revenue Per Share 145.293 | Quarterly Revenue Growth 0.046 | Return On Assets 0.0694 |
The market value of DaVita HealthCare is measured differently than its book value, which is the value of DaVita that is recorded on the company's balance sheet. Investors also form their own opinion of DaVita HealthCare's value that differs from its market value or its book value, called intrinsic value, which is DaVita HealthCare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DaVita HealthCare's market value can be influenced by many factors that don't directly affect DaVita HealthCare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DaVita HealthCare's value and its price as these two are different measures arrived at by different means. Investors typically determine if DaVita HealthCare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DaVita HealthCare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.